Welcome to our dedicated page for LHSIF news (Ticker: LHSIF), a resource for investors and traders seeking the latest updates and insights on LHSIF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LHSIF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LHSIF's position in the market.
Liberty Health Sciences (CSE: LHS) (OTCQX: LHSIF) announced the opening of its 30th dispensary in Port Charlotte, Florida, enhancing its retail footprint in the region. The new facility is strategically located at 4656 Tamiami Trail and will operate daily with set hours. Additionally, the company will open its 31st dispensary in Fort Pierce, featuring a drive-thru service, pending health department approvals. This expansion reflects Liberty's commitment to increasing its access across Florida and meeting patient needs more effectively.
Liberty Health Sciences (CSE: LHS) announced that shareholders approved the acquisition by Ayr Wellness at a special meeting on Feb 23, 2021. The Arrangement Resolution required two-thirds approval from both Liberty Shareholders and Securityholders, which was achieved. A total of 204,539,150 shares (57.19%) were represented, with 183,396,853 votes for the resolution (94.80% approval). The transaction remains subject to regulatory and court approvals. Liberty’s Interim CEO, George Gremse, expressed optimism about completing the transaction promptly.
Liberty Health Sciences has announced a major expansion of its LHS360 cannabis cultivation facility in Florida, increasing capacity to 490,000 square feet by end of 2021. The project will create over 200 jobs and support the company's growth in cannabis products, including edibles. A new Ethanol Extraction Lab will enhance processing capabilities by extracting over 100 kg of biomass per day, significantly boosting product output. The company also secured approvals for advanced indoor farming and agricultural initiatives, aiming to meet the growing demand in the cannabis edibles market, projected to reach $4.1 billion by 2022.
Liberty Health Sciences Inc. (OTCQX: LHSIF) has partnered with Seed Junky™ Genetics, a California cannabis pioneer, to introduce award-winning cannabis strains in Florida. The collaboration aims to distribute SJG's premium genetics, known for high THC levels exceeding 30%, to Liberty's Florida locations between November and December 2020. The company also recently completed a new tissue culture lab to enhance genetic development. This partnership represents a significant step forward in providing high-quality cannabis products to patients in Florida.
